Q32 Bio Inc. (NASDAQ:QTTB) Given Average Recommendation of “Moderate Buy” by Brokerages

Q32 Bio Inc. (NASDAQ:QTTB) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.50.

QTTB has been the subject of a number of research reports. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Zacks Research lowered Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Monday. Cantor Fitzgerald started coverage on Q32 Bio in a report on Monday. They issued an “overweight” rating for the company. Mizuho started coverage on Q32 Bio in a research note on Friday. They issued an “outperform” rating and a $14.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Q32 Bio in a report on Tuesday, May 5th.

Insider Buying and Selling at Q32 Bio

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer directly owned 89,104 shares in the company, valued at $401,859.04. The trade was a 10.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 16,706 shares of company stock worth $75,344. 40.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. HRT Financial LP boosted its stake in shares of Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock worth $81,000 after acquiring an additional 9,862 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Q32 Bio by 75.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock worth $225,000 after acquiring an additional 15,000 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Q32 Bio during the 2nd quarter worth about $25,000. Geode Capital Management LLC boosted its stake in shares of Q32 Bio by 19.9% during the 4th quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after acquiring an additional 17,617 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Q32 Bio during the 4th quarter worth about $68,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Price Performance

Shares of NASDAQ QTTB opened at $5.50 on Friday. Q32 Bio has a 52 week low of $1.35 and a 52 week high of $8.05. The business’s 50 day moving average price is $6.08 and its 200 day moving average price is $4.39. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.04. The firm has a market cap of $93.28 million, a P/E ratio of 2.07 and a beta of -0.05.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14. On average, sell-side analysts expect that Q32 Bio will post -2.02 earnings per share for the current year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.